FDA Approves OTC Naloxone Nasal Spray Rextovy for Opioid Overdose
The FDA has approved Rextovy, a 4 mg naloxone nasal spray, for over-the-counter use in treating opioid overdose.
Asset / Drug
Drug and asset intelligence for Rextovy with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.